Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 1.7% – Here’s Why

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) were down 1.7% during trading on Monday . The stock traded as low as $1.16 and last traded at $1.17. Approximately 8,584 shares were traded during trading, a decline of 84% from the average daily volume of 52,941 shares. The stock had previously closed at $1.19.

Analysts Set New Price Targets

PSTV has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Plus Therapeutics in a research report on Tuesday, November 26th. Ascendiant Capital Markets dropped their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th.

Plus Therapeutics Stock Down 1.7 %

The firm has a market cap of $6.90 million, a price-to-earnings ratio of -0.46 and a beta of 0.70. The company’s fifty day moving average is $1.21 and its 200 day moving average is $1.40.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.